The polymeric antigen BLSOmp31 confers protection against Brucella ovis infection in rams.
We have engineered the polymeric vaccine BLSOmp31 by decorating the highly immunogenic and decameric Brucella lumazine synthase with an exposed loop of the Brucella outer membrane protein Omp31. In the present study, we have immunized different groups of rams with the recombinant chimera rBLSOmp31 in two different adjuvants (Incomplete Freund Adjuvant-IFA and QUIL A) and with the plasmid pCIBLSOmp31 administered either by i.m. injection alone or by using electroporation. In addition, we have used a heterologous prime-boost strategy consisting of repeated pCIBLSOmp31 electroporation priming followed by a single protein boost. Both, chimera rBLSOmp31 in IFA and the prime-boost strategy induced the highest IgG specific antibodies with bacteriolytic activity. While electroporation-enhanced humoral immune responses as compared to pCIBLSOmp31 injection alone, the highest levels of specific IFN-gamma and protection against bacterial challenge were achieved with prime-boost (76%) and chimera rBLSOmp31 in IFA (63%). Taken together these results strongly support the usefulness of the chimera BLSOmp31 as a vaccine against Brucella ovis in ovine brucellosis.
Estein
Silvia M
SM
Departamento de Sanidad Animal y Medicina Preventiva, Universidad Nacional del Centro de la Provincia de Buenos Aires, Tandil, Argentina. silmares@vet.unicen.edu.ar
Fiorentino
María A
MA
Paolicchi
Fernando A
FA
Clausse
María
M
Manazza
Jorge
J
Cassataro
Juliana
J
Giambartolomei
Guillermo H
GH
Coria
Lorena M
LM
Zylberman
Vanesa
V
Fossati
Carlos A
CA
Kjeken
Rune
R
Goldbaum
Fernando A
FA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000372:Agglutination Tests; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D002004:Brucella Vaccine / Q000276:immunology*; D042061:Brucella ovis / Q000276:immunology; D002006:Brucellosis / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary*; D003165:Complement System Proteins / Q000276:immunology; D018274:Electroporation; D005620:Freund's Adjuvant / Q000276:immunology; D056724:Immunity, Humoral; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000276:immunology; D008055:Lipids / Q000276:immunology; D008297:Male; D009097:Multienzyme Complexes / Q000276:immunology; D010957:Plasmids; D062605:Quillaja Saponins; D011994:Recombinant Proteins / Q000276:immunology; D012503:Saponins / Q000276:immunology; D012756:Sheep; D012757:Sheep Diseases / Q000276:immunology* / Q000517:prevention & control
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins; D002004:Brucella Vaccine; D007074:Immunoglobulin G; D008055:Lipids; D009097:Multienzyme Complexes; D062605:Quillaja Saponins; D011994:Recombinant Proteins; D012503:Saponins; C114843:incomplete Freund's adjuvant; C046386:Quil A; D007371:Interferon-gamma; C044822:6,7-dimethyl-8-ribityllumazine synthase; D003165:Complement System Proteins; D005620:Freund's Adjuvant